Hydroxyl-containing compounds

Details Hydroxyl-containing compounds Hydroxyl-containing compounds

1999-07-27

2004-02-17

Raymond, Richard L. (Department: 1611)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S263200, C544S267000, C436S098000

Reexamination Certificate

active

06693105

ABSTRACT:

TECHNICAL FIELD OF THE INVENTION
The invention provides a class of substituted hydroxyl-containing compounds for use in inhibiting specific intra-cellular signaling events often induced by noxious or inflammatory stimuli. More specifically, the inventive compounds have at least one hydroxyl-containing substituent bonded to a core moiety. The inventive compounds are useful antagonists to control intracellular levels of specific non-arachidonyl sn-2 unsaturated phosphatidic acids and corresponding phosphatidic acid-derived diacylglycerols which occur in response to cellular proliferative stimuli.
BACKGROUND ART
Pentoxifylline (1-(5-oxohexyl)-3,7-dimethylxanthine), abbreviated PTX and disclosed in U.S. Pat. Nos. 3,422,307 and 3,737,433, is a xanthine derivative which has seen widespread medical use for the increase of blood flow. Metabolites of PTX were summarized in Davis et al.,
Applied Environment Microbial.
48:327, 1984. One such metabolite, 1-(5-hydroxyhexyl)-3,7-dimethylxanthine, designated M1 and disclosed in U.S. Pat. Nos. 4,515,795 and 4,576,947, increases cerebral blood flow. In addition, U.S. Pat. Nos. 4,833,146 and 5,039,666 disclose use of tertiary alcohol analogs of xanthine for enhancing cerebral blood flow.
U.S. Pat. No. 4,636,507 discloses that PTX and M1 stimulate chemotaxis in polymorphonuclear leukocytes in response to a chemotaxis stimulator. PTX and related tertiary alcohol substituted xanthines inhibit activity of certain cytokines to affect chemotaxis (U.S. Pat. Nos. 4,965,271 and 5,096,906). Administration of PTX and GM-CSF decrease tumor necrosis factor (TNF) levels in patients undergoing allogeneic bone marrow transplant (Bianco et al.,
Blood
76: Supplement 1 (522A), 1990). Reduction in bone marrow transplant-related complications accompanied reduction in assayable levels of TNF. However, in normal volunteers, TNF levels were higher among PTX recipients. Therefore, elevated levels of TNF are not the primary cause of such complications.
Therefore, effective therapeutic compounds that are safe and effective for human or animal administration and that can maintain cellular homeostasis in the face of a variety of inflammatory stimuli are needed. The invention is a result of research conducted in looking for such compounds.
SUMMARY OF THE INVENTION
We have found a genus of compounds useful in a large variety of therapeutic indications for treating or preventing disease mediated by intracellular signaling through one or two specific intracellular signaling pathways. In addition, the inventive compounds and pharmaceutical compositions are suitable for normal routes of therapeutic administration (e.g., parenteral, oral, topical, etc.) for providing effective dosages.
In one of its aspects, the invention includes a method for treating an individual having a disease or treatment-induced toxicity that is characterized by, or can be treated by inhibiting, an immune response or a cellular response to external or in situ primary stimuli, the cellular response being mediated through a specific phospholipid-based second messenger described herein. The second messenger pathway is activated in response to various noxious, proinflammatory or proliferative stimuli characteristic of a variety of disease states. More specifically, the invention includes methods for treating or preventing clinical symptoms of various disease states or reducing toxicity of other treatments by inhibiting cellular signaling through a second messenger pathway involving signaling through a non-arachidonyl phosphatidic acid intermediate. Treatment is carried out by administering an inventive compound, and pharmaceutical compositions thereof, having the formula:
(R)
j
—(CORE MOIETY),
including resolved enantiomers and/or diastereomers, hydrates, salts, solvates and mixtures thereof, wherein j is an integer from one to three, the core moiety comprises a bicyclic ring structure having at least one heterocyclic ring that contains five to six ring atoms and up to two nitrogen heteroatoms, R is selected from the group consisting of hydrogen, halogen, hydroxyl, amino, substituted or unsubstituted benzyl, C
1-6
alkyl or C
1-6
alkenyl, preferably the alkyl or alkenyl groups being substituted by an hydroxy, halogen and dimethylamine and/or interrupted by an oxygen atom. Preferred R include, but are not limited to, methyl, ethyl, isopropyl, n-propyl, isobutyl, n-butyl, t-butyl, 2-hydroxyethyl, 3-hydroxypropyl, 3-hydroxy-n-butyl, 2-methoxyethyl, 4-methoxy-n-butyl, 5-hydroxyhexyl, 2-bromopropyl, 3-dimethylaminobutyl, 4-chloropentyl, and the like. Particularly preferred R are ethyl, methyl, or H, and most preferably, methyl or H. At least one R has the formula I:
wherein n is an integer from 1 to 20, preferably an integer from 3 to 15, more preferably from 6 to 12, and at least one of X or Y is —OH. If only one of X or Y is —OH, then the other X or Y is hydrogen, CH
3
—, CH
3
—CH
2
—, CH
3
—(CH
2
)
2
—, or (CH
3
)
2
—CH
2
—, and W
1
, W
2
, and W
3
are independently hydrogen, CH
3
—, CH
3
—CH
2
—, CH
3
—(CH
2
)
2
—, or (CH
3
)
2
—CH
2
—, wherein X, Y, W
1
, W
2
, and W
3
alkyl groups may be substituted by an hydroxyl, halo or dimethylamino group and/or interrupted by an oxygen atom, hydrogen or alkyl (C
1-4
). Especially preferred compounds have X and Y both being —OH and each of W
1
, W
2
, and W
3
being hydrogen or methyl. Preferably R having formula I structure is bonded to a ring nitrogen.
Exemplary bicyclic core moieties include, without limitation, substituted or unsubstituted: xanthinyl, dioxotetrahydropteridine, phthalimide, homophthalimide, benzoyleneurea and quinazoline-4(3H)-one. In one preferred embodiment, the core moiety is xanthine or a xanthine derivative.
Especially preferred xanthine compounds have the following formula II:
wherein R is selected from the foregoing members. Most preferably, a single R having formula I above is bonded to the N
1
xanthine nitrogen in formula II or each of two formula I R are bonded to N
1
and N
7
xanthine nitrogens, respectively. Remaining R substituents are preferably selected from the group consisting of hydrogen, methyl, fluoro, chloro and amino.
The compounds of the present invention are typically used as pharmaceutical compositions combined with a pharmaceutically acceptable excipient. The pharmaceutical composition may be formulated for oral, parenteral, ocular or topical administration to a patient.
In one of its aspects, the invention provides a method for modulating the response of a target cell to a stimulus by contacting the target cell with an effective amount of a compound of the invention. The stimulus is capable of elevating the cellular level of non-arachidonate phosphatidic acid (PA) and diacylglycerol(DAG) derived therefrom, and the compound is provided in an amount that is effective to reduce these elevated levels by an amount that is equal to or greater than that produced by treating the cells with 0.5 mmol pentoxifylline (PTX).
In another of its aspects, the invention provides a method for treating an individual having a disease or treatment-induced toxicity, mediated through a specific phospholipid-based second messenger, by administering a pharmaceutically effective amount of a compound of the invention. The disease is characterized by or can be treated by inhibiting an immune response or cellular response to external or in situ primary stimuli.
The disease or treatment-induced toxicity is selected from the group consisting of: tumor progression involving tumor stimulation of blood supply (angiogenesis) by production of fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF) or platelet-derived growth factor (PDGF); tumor invasion and formation of metastases through adhesion molecule binding, expressed by vascular endothelial cells (VCAM and ICAM); tissue invasion through tumor metalloprotease production such as MMP-9; autoimmune diseases caused by dysregulation of the T cell or B cell immune systems, treatable by suppression of the T cell or B cell responses; acute allergic reactions including, but not limit

Affiliated with

Also associated with

Rating

Hydroxyl-containing compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Hydroxyl-containing compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hydroxyl-containing compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3332385